Clinical Trials Sponsored by Tibotec BVBA

Total 271 results

Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands
Tibotec BVBA

Completed

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Hepatitis C
Tibotec BVBA

Completed

A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

Hepatitis C, Chronic

France, United Kingdom, Sweden
Tibotec BVBA

Completed

A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants

Healthy
Tibotec BVBA

Completed

TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions

Healthy Volunteer
Tibotec BVBA

Completed

TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer

HIV | Tuberculosis
Tibotec BVBA

Completed

VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer

Hepatitis C | HIV | HCV | AIDS
Tibotec BVBA

Completed

TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)

HIV Infections

South Africa
Tibotec BVBA

Completed

A Study of TMC207 in Patients With Moderately Impaired Hepatic Function

Moderate Hepatic Impairment
Tibotec BVBA

Completed

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis

Tuberculosis
Tibotec BVBA

Completed

VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.

Hepatitis C | HIV | Telaprevir
Tibotec BVBA

Terminated

TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin

Hepatitis C Virus

Poland, Netherlands
Tibotec BVBA

Completed

VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram

Hepatitis C
Tibotec BVBA

Completed

VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.

Kidney Diseases | Hepatitis C
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

Hepatitis C
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State

Healthy Participants
Vertex Pharmaceuticals Incorporated
Tibotec BVBA

Completed

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

Hepatitis C | Opioid-Related Disorders

United States
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Hepatitis C
Rousselot BVBA

Not yet recruiting

An Open Label, Dose-escalation Study, Assessing the Safety and Tolerability of a Collagen Peptide

Tolerance

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
MSD Belgium BVBA

Completed

BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium (BEPACT- Lung)

Stage IV Non-small Cell Lung Cancer

Belgium
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Rousselot BVBA
BioTeSys GmbH

Active, not recruiting

Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects

Healthy | Prediabetic State

Germany
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Janssen Infectious Diseases BVBA

Withdrawn

A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis

Multi-drug Resistant Tuberculosis

China, Ukraine, Taiwan, Korea, Republic of, Peru, Brazil, Estonia, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey, Georgia, Mexico, Cambodia, Ethiopia
Janssen Infectious Diseases BVBA

Completed

A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment

Hepatic Impairment

Germany, Czech Republic
KU Leuven
Rousselot BVBA

Completed

Effects of Collagen Peptide Supplementation on Muscle and Tendon Damage and Function

Healthy Male Subjects | Exercise

Belgium
Rousselot BVBA
BioTeSys GmbH

Completed

Impact of the Source and Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects

Bioavailability

Germany
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
Janssen Infectious Diseases BVBA

Approved for marketing

Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis

Tuberculosis

Russian Federation, Lithuania
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Janssen Infectious Diseases BVBA

Completed

A Study to Assess the Relative Bioavailability of TMC207 Following Single-Dose Administrations of Two Pediatric Formulations in Healthy Adult Participants

Healthy | Biological Availability

Netherlands
Rousselot BVBA
BioTeSys GmbH

Active, not recruiting

Investigation of the Bioavailability of Marine Based Collagen Peptides in Healthy Subjects

Healthy

Germany
TripleMed B.V.
Fakkel bvba

Completed

ANEUFIX for Endoleaks Type II (ACP-T5)

Abdominal Aortic Aneurysm

Netherlands
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Infectious Diseases BVBA

Completed

To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

Tuberculosis

China, Ukraine, Korea, Republic of, Peru, Estonia, Kenya, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey
Janssen Infectious Diseases BVBA

Completed

A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir

Healthy

Belgium
Janssen Infectious Diseases BVBA

Completed

TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

Tuberculosis

South Africa, Peru, Latvia, Philippines, Russian Federation, Thailand, Brazil, India
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir

Healthy Participants

Netherlands
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

HIV Infections | HIV-1 | Human Immunodeficiency Virus Type 1

United States, Australia, France, United Kingdom, Taiwan, Spain, Argentina, Portugal, Romania, South Africa, Canada, Denmark, Sweden, Netherlands, Brazil, Puerto Rico, Austria, Russian Federation, Thailand, Mexico
Tibotec Pharmaceuticals, Ireland

Completed

TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers

Hepatitis C

Hong Kong
Tibotec Pharmaceuticals, Ireland

Approved for marketing

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

HIV Infections

United States, Belgium, Germany, Taiwan, Spain, Switzerland, Mexico, Slovenia, Malaysia, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Russian Federation, Czech Republic, Puerto Rico, Thailand, Hungary, Luxembourg, Venezuela
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Healthy

Germany
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone

Hepatitis C

Canada
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435

Hepatitis C Virus

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

HIV Infections | HIV-1

United States, France, Spain, Canada, South Africa, Argentina, Brazil, Romania
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

HIV

United States, France, United Kingdom, Germany, Taiwan, Spain, Belgium, Chile, Costa Rica, Panama, South Africa, Canada, Greece, Singapore, Argentina, Mexico, Puerto Rico, Austria, Russian Federation, Thailand, Australia, Denmark, S... and more
Tibotec Pharmaceuticals, Ireland

Completed

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Human Immunodeficiency Virus Type 1
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light

Hepatitis C Virus

3

Subscribe